Naveris Inc.TM is a molecular diagnostics company developing and commercializing novel blood and saliva tests to transform the early detection and clinical management of viral-driven cancers. The company’s NavDx® blood test, which uses proprietary technology to detect tumor-tissue–modified viral (TTMV®)-HPV DNA, is ordered by more than 150 leading medical centers across the United States.